On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson's disease: studies with the P2X(7) receptor antagonist A-438079.
The role of the ATP-gated receptor, P2X(7), has been evaluated in the unilateral 6-OHDA rat model of Parkinson's disease using the P2X(7) competitive antagonist A-438079. Nigral P2X(7) immunoreactivity was mainly located in microglia but also in astroglia. A-438079 partially but significantly prevented the 6-OHDA-induced depletion of striatal DA stores. However, this was not associated with a reduction of DA cell loss. Blockade of P2X(7) receptors may represent a novel protective strategy for striatal DA terminals in Parkinson's disease and warrants further future investigation.
Marcellino
Daniel
D
Department of Neuroscience, Karolinska Institutet, 17177 Stockholm, Sweden. Daniel.Marcellino@ki.se
Suárez-Boomgaard
Diana
D
Sánchez-Reina
María Dolores
MD
Aguirre
José A
JA
Yoshitake
Takashi
T
Yoshitake
Shimako
S
Hagman
Beth
B
Kehr
Jan
J
Agnati
Luigi F
LF
Fuxe
Kjell
K
Rivera
Alicia
A
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D018663:Adrenergic Agents / Q000633:toxicity; D000704:Analysis of Variance; D000818:Animals; D001921:Brain / Q000378:metabolism; D002452:Cell Count / Q000379:methods; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism*; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D006719:Homovanillic Acid / Q000378:metabolism; D008297:Male; D009410:Nerve Degeneration / Q000150:complications; D009434:Neural Pathways / Q000378:metabolism; D016627:Oxidopamine / Q000633:toxicity; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy* / Q000209:etiology; D058919:Purinergic P2 Receptor Antagonists; D011725:Pyridines / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018048:Receptors, Purinergic P2 / Q000378:metabolism*; D058486:Receptors, Purinergic P2X7; D018709:Statistics, Nonparametric; D013777:Tetrazoles / Q000627:therapeutic use*
C523668:3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine; D018663:Adrenergic Agents; D005904:Glial Fibrillary Acidic Protein; C546470:P2rx7 protein, rat; D058919:Purinergic P2 Receptor Antagonists; D011725:Pyridines; D018048:Receptors, Purinergic P2; D058486:Receptors, Purinergic P2X7; D013777:Tetrazoles; D015102:3,4-Dihydroxyphenylacetic Acid; D016627:Oxidopamine; D004298:Dopamine; D006719:Homovanillic Acid
J Immunol. 2006 Apr 1;176(7):3877-83
16547218
Br J Pharmacol. 2007 Jul;151(5):571-9
17471177
Trends Neurosci. 2006 May;29(5):257-62
16564580
Eur J Pharmacol. 1968 Dec;5(1):107-10
5718510
Neurosci Lett. 2000 May 12;285(2):87-90
10793233
J Pharmacol Exp Ther. 2006 Dec;319(3):1376-85
16982702
J Histochem Cytochem. 1994 Aug;42(8):1033-41
8027523
J Neurosci. 2004 Jul 14;24(28):6307-14
15254086
J Neural Transm Suppl. 2006;(70):71-83
17017512
Neuroreport. 2008 Apr 16;19(6):657-60
18382281
J Mol Endocrinol. 2007 Mar;38(3):365-76
17339399
J Med Chem. 2006 Jun 15;49(12):3659-66
16759108
J Biol Chem. 2007 Dec 28;282(52):37350-8
17962183
FEBS Lett. 2005 Jul 4;579(17):3783-8
15978588
EMBO J. 2006 Nov 1;25(21):5071-82
17036048
Neuroscience. 2006;137(4):1447-61
16387447
Pain. 2005 Apr;114(3):386-396
15777864
Brain Res Rev. 2008 Aug;58(2):453-8
18457883
Brain Res. 2005 Feb 8;1033(2):216-20
15694927
Science. 1996 May 3;272(5262):735-8
8614837